For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis is pleased to announce top line results from the second large-scale global Phase III trial (CF302) of Bronchitol® (mannitol inhalation powder) in patients with cystic fibrosis (CF).
The results support the early and sustained improvement in lung function in cystic fibrosis patients seen in the first phase III study (CF301) and Pharmaxis will now move forward to meet the U.S. Food & Drug Administration (FDA) later this year to discuss a New Drug Application (NDA) for Bronchitol.
Read full media release - pdf